Arbutus BiopharmavsJohnson & Johnson

ABUS and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

ABUS

Arbutus Biopharma Corporation

$4.02

Value $799M

-1.23%
ABUS's page

Arbutus Biopharma (ABUS) has a market value of $799M and Johnson & Johnson (JNJ) $652B. Over the last year, with dividends, ABUS moved -5.9% and JNJ +36.6%. The P/E is 3.6 for ABUS and 40.5 for JNJ. Dividend yield: ABUS none, JNJ 1.95%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABUS$799M

    JNJ$652B

    JNJ is 816 times ABUS

  • Revenue, 12 months

    ABUS$181M

    JNJ$99.3B

    JNJ is 547 times ABUS

  • Net income, 12 months

    ABUS$220M

    JNJ$16.1B

    JNJ is 73 times ABUS

  • Operating margin

    ABUS81.1%

    JNJ–

  • ROIC

    ABUS76.6%

    JNJ12.4%

    64.2 points apart

  • P/E

    ABUS3.6

    JNJ40.5

    JNJ is 11 times ABUS

  • Dividend yield

    ABUS0.0%

    JNJ2.0%

    2.0 points apart

  • 5-year return

    ABUS+21.8%

    JNJ+90.9%

    69.1 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABUS+21.8%

JNJ+90.9%

5010015020020222023202420252026
Returns by period
PeriodABUSWith dividendsJNJWith dividends
1 year since November 19, 2025-5.9%Price -5.9%+36.6%Price +33.6%
3 years since November 20, 2023+118.5%+29.8% a yearPrice +118.5%+94.9%+24.9% a yearPrice +80.4%
5 years since November 19, 2021+21.8%+4.0% a yearPrice +21.8%+90.9%+13.8% a yearPrice +66.0%
10 years since November 21, 2016+48.9%+4.1% a yearPrice +48.9%+206.5%+11.9% a yearPrice +135.2%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABUSArbutus BiopharmaJNJJohnson & Johnson

Valuation

ABUSJNJ
Valuation
Price$4.02$270.47
Market value$799M$652B
Enterprise value (EV)$461M$679B
P/E3.640.5
P/E, 5-year median–21.9
P/B9.38.0
EV/EBIT3.138.3
Free cash flow yield27.7%3.2%

Results and growth

ABUSJNJ
Results and growth
Revenue, 12 months$181M$99.3B
Net income, 12 months$220M$16.1B
Free cash flow, 12 months$221M$20.6B
Earnings per share, 12 months$1.13$6.59
Revenue growth, year on year128.2%6.1%
Revenue growth a year, past+15.3%over 5 years+2.7%over 5 years
EPS growth a year, past–+14.9%over 5 years

Margins and returns on capital

ABUSJNJ
Margins and returns on capital
Gross margin–67.6%
Operating margin81.1%–
Net margin121.2%16.2%
ROIC76.6%12.4%
ROE144.9%19.7%

Balance sheet

ABUSJNJ
Balance sheet
Cash$337M$17.2B
Total debt$328.0K$44.7B
Net debt / EBITDA-2.31.1
Interest cover2,299.4×18.0×

Dividends and buybacks

ABUSJNJ
Dividends and buybacks
Dividend yield–2.0%
Dividend per share, 12 months–$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield–0.9%
Shareholder yield–2.9%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABUS or JNJ

Didn't find what you were looking for?

Ask us
Which is bigger, Arbutus Biopharma or Johnson & Johnson?

By market value, Johnson & Johnson ($652B) is about 816.1 times Arbutus Biopharma ($799M), at today's prices.

How did ABUS and JNJ stock do over the last 10 years?

Since November 21, 2016, ABUS's price moved +48.9% and JNJ's +135.2%. With dividends: ABUS +48.9% (+4.1% a year), JNJ +206.5% (+11.9% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABUS or JNJ?

The dividend yield at today's price is none for Arbutus Biopharma and 1.95% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.

What is the P/E of ABUS and JNJ?

At today's price, the P/E is 3.6 for ABUS and 40.5 for JNJ. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, Arbutus Biopharma or Johnson & Johnson?

Over the last twelve months, the net margin was 121.2% for Arbutus Biopharma and 16.2% for Johnson & Johnson, and the operating margin 81.1% and –. Revenue was $181M and $99.3B.

Which is the better investment, Arbutus Biopharma or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.